
FBRX
Forte Biosciences Inc.
$15.76
+$0.97(+6.56%)
18
Overall
--
Value
18
Tech
--
Quality
Market Cap
$153.30M
Volume
88.29K
52W Range
$4.11 - $28.68
Target Price
$63.33
Order:
Income Statement
Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
Total Revenue | $36.0K | -- | -- | -- | -- | -- | ||
Total Revenue | $36.0K | -- | -- | -- | -- | -- | ||
GROSS PROFIT | ||||||||
Gross Profit | $36.0K | -- | -- | -- | -- | -- | ||
OPERATING EXPENSES | ||||||||
Operating Expenses | $4.1M | $46.3M | $21.5M | $13.9M | $32.5M | $36.6M | ||
Research & Development | $2.7M | $42.1M | $13.9M | $5.6M | $21.9M | $20.7M | ||
Research Expense | $2.7M | $42.1M | $13.9M | $5.6M | $21.9M | $20.7M | ||
Selling, General & Administrative | $1.4M | $4.2M | $7.6M | $8.3M | $10.6M | $15.4M | ||
General & Administrative Expenses | $1.4M | $4.2M | $7.6M | $8.3M | $10.6M | $15.4M | ||
Salaries & Wages | -- | -- | -- | -- | $3.3M | $3.1M | ||
Depreciation & Amortization | $-843.0K | -- | -- | -- | -- | -- | ||
Depreciation & Amortization | $-843.0K | -- | -- | -- | -- | -- | ||
Other Operating Expenses | $-61.5M | $52.0K | $100.0K | $19.0K | $-94.0K | $-160.0K | ||
OPERATING INCOME | ||||||||
Operating income | $-4.1M | $-46.3M | $-21.5M | $-13.9M | $-32.5M | $-36.6M | ||
EBITDA | $-4.1M | $-14.2M | $-21.4M | $-13.9M | $-32.6M | $-36.8M | ||
NON-OPERATING ITEMS | ||||||||
Interest Expense (Non-Operating) | $3.8M | -- | -- | $-162.0K | $-1.1M | $-1.3M | ||
Intinc | $1.6M | -- | -- | -- | -- | -- | ||
Net Non-Operating Interest Income/Expense | $-2.3M | -- | -- | $-162.0K | $1.1M | $1.3M | ||
Gain on Sale of Securities | $33.0K | -- | -- | -- | $4.0K | $7.0K | ||
Other Income/Expense | $5.0K | $205.0K | $222.0K | $-145.0K | $114.0K | $190.0K | ||
Other Special Charges | $-5.0K | $-205.0K | $-222.0K | $-145.0K | $-114.0K | $-190.0K | ||
SPECIAL ITEMS | ||||||||
Restructring And Mn A Income | $-200.0K | -- | -- | -- | -- | -- | ||
Special Income Charges | $200.0K | -- | -- | -- | -- | -- | ||
Other Impairment Of Capital Assets | -- | -- | $61.0K | -- | -- | -- | ||
PRE-TAX INCOME | ||||||||
EBIT | $-4.1M | $-14.2M | $-21.5M | $-13.9M | $-32.6M | $-36.8M | ||
Pre-Tax Income | $-4.1M | $-46.5M | $-21.7M | $-13.9M | $-31.5M | $-35.0M | ||
INCOME TAX | ||||||||
Tax Provision | $1.0K | $-3.2M | $-67.0K | $-79.0K | -- | $-2.0K | ||
NET INCOME | ||||||||
Net Income | $-4.1M | $-46.5M | $-21.7M | $-13.9M | $-31.5M | $-35.5M | ||
Net Income (Continuing Operations) | $-4.1M | $-46.5M | $-21.7M | $-13.9M | $-31.5M | $-35.5M | ||
Net Income (Discontinued Operations) | $-4.1M | $-46.5M | $-21.7M | $-13.9M | $-31.5M | $-35.5M | ||
Net Income (Common Stockholders) | $-4.1M | $-46.5M | $-21.7M | $-13.9M | $-31.5M | $-35.5M | ||
Normalized Income | $-3.2M | $-49.8M | $-21.7M | -- | -- | $-35.0M | ||
TOTALS | ||||||||
Total Expenses | $4.1M | $46.3M | $21.5M | $13.9M | $32.5M | $36.6M | ||
SHARE & EPS DATA | ||||||||
Average Shares Outstanding | $945.2K | $294.4K | $558.7K | $695.3K | $1.3M | $2.9M | ||
Average Shares Outstanding (Diluted) | $945.2K | $294.4K | $558.7K | $695.3K | $1.3M | $2.9M | ||
Shares Outstanding | $956.0K | $540.4K | $590.5K | $840.3K | $1.5M | $6.6M | ||
Basic EPS | $-67.25 | $-158 | $-38.75 | $-20 | $-25 | $-12.17 | ||
Basic EPS (Continuing Operations) | $-67.25 | $-158 | $-38.75 | $-20 | $-25 | $-12.17 | ||
Diluted EPS | $-67.25 | $-158 | $-38.75 | $-20 | $-25 | $-12.17 | ||
Diluted EPS (Continuing Operations) | -- | -- | -- | $-20 | $-25 | $-12.17 | ||
OTHER METRICS | ||||||||
Gain On Sale Of P P E | $-1.2M | -- | -- | -- | -- | -- | ||
Other Gand A | $1.4M | $4.2M | $7.6M | $8.3M | $10.6M | $15.4M | ||
Realized Capital Gain | $1.4M | -- | -- | -- | -- | -- | ||
Restruct | $-200.0K | -- | -- | -- | -- | -- |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | FBRX | $15.76 | +6.6% | 88.29K |
3 | ||||
4 | ||||
5 | ||||
6 |